Virulence factors are components of pathogens that contribute to their ability to cause disease, and targeting these factors is a central strategy in vaccine development. Vaccines often aim to neutralize or block the action of virulence factors, such as bacterial toxins, surface proteins, or enzymes that enable pathogens to invade host cells or evade the immune system. By preventing the pathogen from expressing these harmful factors, vaccines can significantly reduce the severity of infection or prevent it altogether. For example, vaccines against bacterial diseases like tetanus, diphtheria, and whooping cough focus on neutralizing the toxins that cause damage in the body. Researchers continue to identify new virulence factors for targeting, especially for emerging or drug-resistant pathogens, expanding the range of diseases that can be controlled through vaccination. By focusing on virulence factors, vaccines can provide highly specific and effective protection with fewer side effects.
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Post COVID-19 syndrome is associated with sex and severity of first COVID-19 episode in Honduras
Manuel Antonio Sierra Santos, Central American Technological University, Honduras
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Establishing a platform method for physical appearance assessment of new parenteral pharmaceuticals
Ying Wan, Merck & Co., United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Development of a platform UPLC-CAD method for high-throughput lipid quantitation and characterization in novel mRNA LNPs
Janet Muzulu, Sanofi, United States